MBX Biosciences Statistics

Total Valuation

MBX Biosciences has a market cap or net worth of $1.44 billion. The enterprise value is $1.04 billion.

Market Cap	1.44B
Enterprise Value	1.04B

Important Dates

The last earnings date was Thursday, November 6, 2025, before market open.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

MBX Biosciences has 44.90 million shares outstanding. The number of shares has increased by 1,225.35% in one year.

Current Share Class	44.90M
Shares Outstanding	44.90M
Shares Change (YoY)	+1,225.35%
Shares Change (QoQ)	+2.25%
Owned by Insiders (%)	2.85%
Owned by Institutions (%)	68.26%
Float	26.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.69
P/TBV Ratio	3.70
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 32.95, with a Debt / Equity ratio of 0.00.

Current Ratio	32.95
Quick Ratio	32.60
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -24.43% and return on invested capital (ROIC) is -17.22%.

Return on Equity (ROE)	-24.43%
Return on Assets (ROA)	-16.64%
Return on Invested Capital (ROIC)	-17.22%
Return on Capital Employed (ROCE)	-23.42%
Revenue Per Employee	n/a
Profits Per Employee	-$1.87M
Employee Count	43
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +66.16% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+66.16%
50-Day Moving Average	21.85
200-Day Moving Average	13.86
Relative Strength Index (RSI)	65.05
Average Volume (20 Days)	747,492

Short Selling Information

The latest short interest is 4.63 million, so 10.31% of the outstanding shares have been sold short.

Short Interest	4.63M
Short Previous Month	4.58M
Short % of Shares Out	10.31%
Short % of Float	17.67%
Short Ratio (days to cover)	5.00

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-90.87M
Pretax Income	-80.50M
Net Income	-80.50M
EBITDA	-90.62M
EBIT	-90.87M
Earnings Per Share (EPS)	-$2.39

Full Income Statement

Balance Sheet

The company has $391.67 million in cash and $623,000 in debt, giving a net cash position of $391.05 million or $8.71 per share.

Cash & Cash Equivalents	391.67M
Total Debt	623,000
Net Cash	391.05M
Net Cash Per Share	$8.71
Equity (Book Value)	387.54M
Book Value Per Share	8.67
Working Capital	385.44M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$77.69 million and capital expenditures -$1.23 million, giving a free cash flow of -$78.91 million.

Operating Cash Flow	-77.69M
Capital Expenditures	-1.23M
Free Cash Flow	-78.91M
FCF Per Share	-$1.76

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MBX Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1,225.35%
Shareholder Yield	-1,225.35%
Earnings Yield	-5.61%
FCF Yield	-5.50%

Analyst Forecast

The average price target for MBX Biosciences is $50.71, which is 58.62% higher than the current price. The consensus rating is "Buy".

Price Target	$50.71
Price Target Difference	58.62%
Analyst Consensus	Buy
Analyst Count	8
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	-32.90%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2